KRYS Stock Price | Krystal Biotech Inc P/E, Revenue, EPS, & Forecasts

Krystal Biotech Inc • KRYS

Capital at risk.

About
Metrics
Forecasts
Earnings performance
Financial performance
Sentiment analysis
FAQs

About Krystal Biotech Inc

Ticker

KRYS

Trading on

NASDAQ

ISIN

US5011471027

Industry

Biotechnology

Sector

Healthcare

CEO

Krish S. Krishnan M.B.A., M.S.

Headquarters

2100 Wharton Street, Pittsburgh, PA, United States, 15203

Employees

275

Website

krystalbio.com

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Metrics

BasicAdvanced

Market cap

$5.11B

P/E ratio

34.15

EPS

$5.17

Dividend Yield

0.00%

Beta

0.65

Forward P/E ratio

25.06

EBIDTA

$153M

Ex dividend date

Price & volume

Market cap

$5.11B

Average daily volume

0.4M

90-day return

30-day return

7-day return

Dividends

Dividend per share

$0.00

Dividend yield

0.00%

Forward dividend per share

$0.00

Forward dividend yield

0.00%

Payout ratio

0.00%

Valuation

P/E ratio

34.15

Forward P/E

25.06

PEG ratio

Trailing P/E

34.15

Price to sales

14.22

Price to book

4.67

Earnings

EPS

$5.17

EPS estimate (current quarter)

$1.44

EPS estimate (next quarter)

$1.56

EBITDA

$153M

Revenues (TTM)

$359M

Revenues per share (TTM)

$12.47

Technicals

Beta

0.65

52-week High

$207.84

52-week Low

$122.80

50-day moving average

$150.64

200-day moving average

$155.39

Short ratio

12.3

Short %

20.87%

Management effectiveness

ROE (TTM)

15.61%

ROA (TTM)

9.23%

Profit margin

40.85%

Gross profit margin

$335M

Operating margin

40.93%

Growth

Quarterly earnings growth (YoY)

143.40%

Quarterly revenue growth (YoY)

36.60%

Share stats

Outstanding Shares

28.9M

Float

23M

Insiders %

11.86%

Institutions %

97.44%

Analyst Insights & forecasts

91% Buy

9% Hold

0% Sell

Based on information from 11 analysts.

Average price target

$205.20

Earnings per share (EPS) forecast

windowbar_chart_4_bars

Actual

Expected

Surprise

$0.91

$0.90

1.11%

Q3 • 24Beat

$1.53

$1.85

-17.39%

Q4 • 24Missed

$1.20

$1.03

16.14%

Q1 • 25Beat

$1.29

$1.22

5.74%

Q2 • 25Current

QuarterlyAnnual

Financial Performance

windowbar_chart_4_bars

Income StatementBalance SheetCash Flow

windowbar_chart_4_bars

Revenue

Net income

Profit margin

$88.2M

$35.7M

40.52%

Q1 • 25

$96M

$38.3M

39.91%

Q2 • 25

8.91%

7.28%

-1.50%

QoQ growth

QuarterlyAnnual

Totals assets

Total liabilities

Debt to assets

$1.07B

$89.7M

8.35%

Q1 • 25

$1.14B

$97.7M

8.59%

Q2 • 25

5.95%

8.92%

2.80%

QoQ growth

QuarterlyAnnual

Operating

Investing

Financing

Free cash flow

$31M

$-54.8M

$-12.5M

$24.8M

Q1 • 25

$52.7M

$-10.5M

$1.8M

$50.8M

Q2 • 25

70.26%

-80.78%

-114.41%

105.23%

QoQ growth

QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Krystal Biotech Inc share?

Krystal Biotech Inc shares are currently traded for undefined per share.

How many shares does Krystal Biotech Inc have?

Krystal Biotech Inc currently has 28.9M shares.

Does Krystal Biotech Inc pay dividends?

No, Krystal Biotech Inc doesn't pay dividends.

What is Krystal Biotech Inc 52 week high?

Krystal Biotech Inc 52 week high is $207.84.

What is Krystal Biotech Inc 52 week low?

Krystal Biotech Inc 52 week low is $122.80.

What is the 200-day moving average of Krystal Biotech Inc?

Krystal Biotech Inc 200-day moving average is $155.39.

Who is Krystal Biotech Inc CEO?

The CEO of Krystal Biotech Inc is Krish S. Krishnan M.B.A., M.S..

How many employees Krystal Biotech Inc has?

Krystal Biotech Inc has 275 employees.

What is the market cap of Krystal Biotech Inc?

The market cap of Krystal Biotech Inc is $5.11B.

What is the P/E of Krystal Biotech Inc?

The current P/E of Krystal Biotech Inc is 34.15.

What is the EPS of Krystal Biotech Inc?

The EPS of Krystal Biotech Inc is $5.17.

What is the PEG Ratio of Krystal Biotech Inc?

The PEG Ratio of Krystal Biotech Inc is null.

What do analysts say about Krystal Biotech Inc?

According to the analysts Krystal Biotech Inc is considered a buy.